Unfortunately, the asset base doesn't always reflect in the SP or company value although I agree as long as the company is viable it is getting harder for others to emulate what SYR has done to date (despite the overspend). So current enterprise value doesn't reflect assets - not to mention the resource.
Shorter's can pile in because there's little on the horizon in terms of revenue. Ex China sales might be coming but not at a great rate of knots it seems. Still unclear whether China will or won't issue more permits going forward. Even if the graphite price rises 10-20% SYR will still barely break even at Balama.
Vidalia commissioning is great news but sales generating revenue won't be for some time apparently. It would be nice to get the ramp up to full production earlier but unlikely. So the cash burn continues.
Importantly, the 150 million loan for Balama (should it happen) will take a lot of pressure off in terms of whether they need to raise any more in the short term. The 45kt expansion will take time and by the time it's FID is finalised there should be more clarity in terms of what's happening in and out of China.
Problems solved if sales increase significantly and the graphite price increases significantly. That might scare the shorter's a bit.
- Forums
- ASX - By Stock
- SYR
- General Discussion
General Discussion, page-652
-
- There are more pages in this discussion • 1,015 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SYR (ASX) to my watchlist
|
|||||
Last
32.0¢ |
Change
-0.005(1.54%) |
Mkt cap ! $331.1M |
Open | High | Low | Value | Volume |
33.0¢ | 33.0¢ | 32.0¢ | $658.4K | 2.040M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 81000 | 32.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
32.5¢ | 119731 | 6 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 81000 | 0.320 |
12 | 862725 | 0.315 |
22 | 1020350 | 0.310 |
26 | 1008672 | 0.305 |
41 | 2517497 | 0.300 |
Price($) | Vol. | No. |
---|---|---|
0.325 | 119731 | 6 |
0.330 | 115790 | 5 |
0.335 | 216100 | 7 |
0.340 | 86315 | 5 |
0.345 | 116537 | 6 |
Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
Featured News
SYR (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online